CN105395643A - Rose-angelica sinensis composition for treating Alzheimer's disease and application thereof - Google Patents
Rose-angelica sinensis composition for treating Alzheimer's disease and application thereof Download PDFInfo
- Publication number
- CN105395643A CN105395643A CN201510937743.6A CN201510937743A CN105395643A CN 105395643 A CN105395643 A CN 105395643A CN 201510937743 A CN201510937743 A CN 201510937743A CN 105395643 A CN105395643 A CN 105395643A
- Authority
- CN
- China
- Prior art keywords
- radix angelicae
- angelicae sinensis
- flos rosae
- rosae rugosae
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 26
- 241000775297 Angelica roseana Species 0.000 title abstract 3
- 239000003814 drug Substances 0.000 claims abstract description 34
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 6
- 241000628997 Flos Species 0.000 claims description 52
- 239000007788 liquid Substances 0.000 claims description 21
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 241000244203 Caenorhabditis elegans Species 0.000 abstract description 20
- 241000220317 Rosa Species 0.000 abstract description 12
- 241000382455 Angelica sinensis Species 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000005645 nematicide Substances 0.000 description 21
- 206010033799 Paralysis Diseases 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 235000010603 pastilles Nutrition 0.000 description 12
- 230000007131 anti Alzheimer effect Effects 0.000 description 11
- 230000003387 muscular Effects 0.000 description 10
- 230000001575 pathological effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000001934 delay Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 241001167795 Escherichia coli OP50 Species 0.000 description 3
- 241000244206 Nematoda Species 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 208000033240 Progressive symmetric erythrokeratodermia Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000004886 head movement Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 238000011017 operating method Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000008132 rose water Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine, and in particular, relates to a rose-angelica sinensis composition for treating Alzheimer's disease and an application thereof. The composition contains rose flowers and angelica sinensis. The rose-angelica sinensis composition has a significant therapeutic effect on a caenorhabditis elegans Alzheimer's disease pathology model, can be applied in preparation of drugs for treatment of Alzheimer's disease, and also can be applied in preparation of related health products for prevention and adjuvant treatment of Alzheimer's disease.
Description
Technical field
The invention belongs to technical field of Chinese medicines, be specifically related to a kind of Flos Rosae Rugosae Radix Angelicae Sinensis compositions and application thereof for the treatment of Alzheimer's disease.
Background technology
Alzheimer's disease (Alzheimer'sMdisease, AD), being a kind of based on the nervous system degenerative disease of Progressive symmetric erythrokeratodermia cognitive disorder and memory impairment, is the modal a kind of form of senile dementia.Feature is shown as clinically with dysmnesia, aphasia, agnosia, the infringement of visual space technical ability, n-back test obstacle and the generalized dementia such as personality and behavior change.In dementia patients, proportion is more than 75%.Along with the aggravation of China's aging degree, AD can become one of principal disease affecting senior health and fitness, and effective prevention and therapy AD becomes the another key subjects of pendulum in face of us.
Amyloid beta deposition (aβ protein) and neurofibrillary tangles are the two large key pathological feature of AD.Modern medicine has carried out years of researches to the pathogenesis of AD, but due to its cause of disease complexity, the pathogenesis of this disease is still indefinite so far, and " A β cascade hypothesis " is current by one of well accepted mechanism of scientific circles.This theory thinks that the A β of abnormal deposition in brain in patients is by a series of cascade reactions such as radical reaction, Mitochondrial oxidative damage and inflammatory reactions; directly or indirect action in neuron and neurogliocyte; finally cause neuronal function abnormal or dead; cause cognitive impairment and amnesia, finally cause dementia.In familial Alzheimer disease disease patient, find that amyloid precursor protein (APP) gene and presenilin genes are undergone mutation, cause A β to become this theory evidence the strongest in the overexpression of brain.Therefore amyloid beta has become the generally acknowledged anti-AD drug targets of screening.
The AD cause of disease is complicated, the course of disease is very long and morbidity link is more, need Long-term taking medicine, anti-Alzheimer disease medicine acetylcholinesteraseinhibitors inhibitors (as galantamine) main at present and N-methyl-D-aspartate receptor (nmda receptor) antagonist (as memantine), but said medicine is expensive, hallucination after taking medicine, misunderstanding, dizziness, headache and the side effect such as tired are remarkable, and can only delay, but can not control or reverse conditions of patients.
And Chinese medicine composition has the feature of various active component, Mutiple Targets, can overcome the weak point of Western medicine to a certain extent, the drug candidates making screening from Chinese medicine composition treasure-house be used for the treatment of AD has a extensive future.
Flos Rosae Rugosae is the Chinese medicine of promoting flow of QI and blood simply, Flos Rosae Rugosae chloroform extract is proved to be the rat embryonic neuronal cell axon growth that can promote In vitro culture, and the neuron axon atrophy (Awaleetal., 2011) suppressing A β (25-35) to cause.But still do not know whether rose water decoct has anti-AD effect.Radix Angelicae Sinensis sweet in the mouth, pungent, micro-hardship, warm in nature; Return liver, the heart, spleen channel; Fragrant strongly fragrant row falls apart, and can rise and can fall; Have and enrich blood, invigorate blood circulation, the effect of menstruction regulating and pain relieving.Theory of Chinese medical science is thought when the product being classified as tune blood of enriching blood, and is gynecological's common medicine.
Caenorhabditis elegans (Caenorhabditiselegans) is the research platform of a very useful multifunctional drug screening and mechanism of drug action.Its is cheap, easily cultivate; Generation cycle is short, offspring's number is many, can obtain the consistent individuality of a large amount of background simultaneously, ensures experimental repeatability and adopts large sample amount to test, thus get rid of the impact of individual variation; With higher organism high conservative (KalettaandHengartner, 2006) in gene and molecular pathway.It from the bridge being sieved to horizontal medicine in Mice Body at the beginning of the horizontal medicine of cells in vitro and sieving again, is more and more subject to the favor of pharmacy man as one.The arrhythmia medicine that devGen company of the U.S. utilizes humanization nematicide to screen is entered clinical research by FDA approval.
The foundation of humanization Caenorhabditis elegans AD pathological model people source A β 1-42 gene is proceeded to Myosin promoter downstream and reaches by temperature control table, this nematicide strain can at 15 DEG C of normal growths, under being transferred to 25 DEG C of conditions, A β 1-42 expresses and accumulates at its intramuscular, causes nematicide lose motor capacity and benumb.Add test medicine and can delay muscular paralysis phenotype, the percentage ratio that its result accounts for tested nematode population quantity with muscular paralysis nematode population represents.Do not benumb nematicide ratio higher, medicine anti-AD effect is more remarkable.This model is used to anti-AD disease mechanism and anti-AD medicine and material standed for study on mechanism (Link, 1995 already; 2001).
Based on above-mentioned present Research, the invention provides a kind of Flos Rosae Rugosae Radix Angelicae Sinensis compositions for the treatment of Alzheimer's disease, this Flos Rosae Rugosae Radix Angelicae Sinensis compositions plays the anti-AD of synergism.The present invention provides the application of this Flos Rosae Rugosae Radix Angelicae Sinensis compositions simultaneously.
List of references
KalettaT,HengartnerMO.Findingfunctioninnoveltargets:C.elegansasamodelorganism.NatRevDrugDiscov2006,5:387e398.
LinkCD.Expressionofhumanbeta-amyloidpeptideintransgenicCaenorhabditiselegans.ProcNatlAcadSciUSA1995,92:9368e9372.
LinkCD.Transgenicinvertebratemodelsofage-associatedneurodegenerativediseases.MechAgeingDev2001,122:1639e1649.
AwaleS，TohdaC，TezukaTetal.ProtectiveEffectsofRosadamascenaanditsactiveconstituentonAβ(25–35)-inducedneuriticatrophy.Evidence-BasedComplementaryandAlternativeMedicine2011,doi:10.1093/ecam/nep149.
Summary of the invention
The object of the invention is to provide a kind of Flos Rosae Rugosae Radix Angelicae Sinensis compositions for the treatment of Alzheimer's disease, and said composition has the potentiality for the treatment of Alzheimer's disease.
Another object of the present invention is to provide the application of above-mentioned Flos Rosae Rugosae Radix Angelicae Sinensis compositions.
Above-mentioned purpose of the present invention is achieved through the following technical solutions:
Treat a Flos Rosae Rugosae Radix Angelicae Sinensis compositions for Alzheimer's disease, described compositions contains Flos Rosae Rugosae, Radix Angelicae Sinensis.
Treat a Flos Rosae Rugosae Radix Angelicae Sinensis compositions for Alzheimer's disease, described compositions contains the crude drug of following weight ratio: Flos Rosae Rugosae 2-4 part, Radix Angelicae Sinensis 12 parts.
Described Flos Rosae Rugosae Radix Angelicae Sinensis compositions can be applied in the medicine of preparation treatment Alzheimer's disease.
Described Flos Rosae Rugosae Radix Angelicae Sinensis compositions is capsule, tablet, granule, powder, oral liquid, pill as the pharmaceutical preparation of active ingredient.
Described Flos Rosae Rugosae Radix Angelicae Sinensis compositions can be applied in the health product preparing prevention and auxiliary treatment Alzheimer's disease.
Described Flos Rosae Rugosae Radix Angelicae Sinensis compositions is capsule, tablet, granule, powder, oral liquid, pill as the health product dosage form of effective ingredient.
Beneficial effect of the present invention:
1, the present invention tests with Caenorhabditis elegans AD pathological model, and result shows: this Flos Rosae Rugosae Radix Angelicae Sinensis compositions has significant therapeutic effect to Caenorhabditis elegans AD pathological model tool.Significantly can delay the paralysis phenotype of Caenorhabditis elegans AD pathological model, this Flos Rosae Rugosae Radix Angelicae Sinensis compositions is pointed out to have the potentiality for the treatment of Alzheimer's disease, can apply in the medicine of preparation treatment Alzheimer's disease, also can apply in the health product preparing prevention and auxiliary treatment Alzheimer's disease.
2, when Flos Rosae Rugosae and Radix Angelicae Sinensis alone time, under concentration of the present invention, all not there is therapeutical effect to Caenorhabditis elegans AD pathological model, but then there is when the two combinationally uses remarkable anti-AD effect, therefore, in Flos Rosae Rugosae Radix Angelicae Sinensis compositions provided by the invention, Flos Rosae Rugosae and Radix Angelicae Sinensis play the anti-AD of synergism.
Below in conjunction with specific embodiment, technical scheme of the present invention is described in further detail, but protection scope of the present invention is not limited to the following stated.
Accompanying drawing explanation
Fig. 1 Flos Rosae Rugosae and Radix Angelicae Sinensis play the muscular paralysis that synergism delays AD Caenorhabditis elegans
Control-blank group, R50-rose wate decocting liquid low concentration group, R25-rose wate decocting liquid high concentration group; D50-water decoction of Angelica sinensis low concentration group, D25-water decoction of Angelica sinensis high concentration group; D25+R50-Flos Rosae Rugosae Radix Angelicae Sinensis compositions low concentration group, concentration group in D25+R25-Flos Rosae Rugosae Radix Angelicae Sinensis compositions.
Fig. 2 Flos Rosae Rugosae Radix Angelicae Sinensis composition dosage relies on the muscular paralysis that ground delays AD Caenorhabditis elegans
Control-blank group, concentration group in D25+R25-Flos Rosae Rugosae Radix Angelicae Sinensis compositions, D12.5+R12.5-Flos Rosae Rugosae Radix Angelicae Sinensis compositions high concentration group.
Detailed description of the invention
The preparation method of embodiment 1 Flos Rosae Rugosae Radix Angelicae Sinensis compositions
Take Flos Rosae Rugosae 2g, Radix Angelicae Sinensis 12g, add water 400mL, and heated and boiled also keeps 30 minutes, is settled to 200mL, filtration sterilization, for subsequent use.
Take Flos Rosae Rugosae 4g, Radix Angelicae Sinensis 12g, add water 400mL, and heated and boiled also keeps 30 minutes, is settled to 200mL, filtration sterilization, for subsequent use.
Embodiment 2 Flos Rosae Rugosae and Radix Angelicae Sinensis play the muscular paralysis that synergism delays AD Caenorhabditis elegans
1. biomaterial
(1) Caenorhabditis elegans CL4176 is purchased from CaenorhabditisGeneticsCenter (CGC); For transgenic strain, express mankind A β at 25 DEG C of temperature-induced lower muscle specifics
1-42, A β
1-42assemble in muscular tissue, finally cause nematicide to be benumbed, the present embodiment adopts C. Elegans Automatic Screening CL4176 strain as the pathological model of the anti-AD medicine of screening.
(2) escherichia coli OP50 (uracil leaky mutant), purchased from CaenorhabditisGeneticsCenter (CGC), as the food of Caenorhabditis elegans.
2. reagent
(1) solid NGM (NematodeGrowthMedium) medium component and making (being upgraded to example with 1):
| Composition | Content |
| NaCl | 3.00g |
| K 2HPO 4 | 2.34g |
| KH 2PO 4 | 17.23g |
| Peptone | 2.50g |
| Agar | 17.00g |
| Supplement H 2O extremely | 1000mL |
After solid NGM culture medium prepares, high-pressure constant temp sterilizing 20min at 121 DEG C, adds 5mg/mL cholesterol 1mL, 1MMgSO under aseptic operating platform
41mL, 1MCaCl
21mL shakes up, and pours sterilized 9cm culture plate while hot into, about 20mL/ plate.Leave standstill and wait for culture medium solidifying, for subsequent use.
(2) M9 formula of liquid
| Composition | Content |
| Na 2HPO 4 | 6.00g |
| KH 2PO 4 | 3.00g |
| NaCl | 5.00g |
| 1M MgSO 4 | 1.00mL |
| Supplement H 2O extremely | 1000mL |
(3) preparation of lysate: 6.4%NaClO solution and 1MNaOH solution 1:1 mixing by volume.
3. the NGM of preparation containing rose wate decocting liquid is dull and stereotyped
The preparation of rose wate decocting liquid:
Flos Rosae Rugosae 4g, add water 400mL, and heated and boiled also keeps 30 minutes, is settled to 200mL, filtration sterilization, for subsequent use, and rose wate decocting liquid concentration conversion dose of making a living is 20mg/mL.
The preparation of water decoction of Angelica sinensis:
Radix Angelicae Sinensis 12g, add water 400mL, and heated and boiled also keeps 30 minutes, is settled to 200mL, filtration sterilization, for subsequent use, and water decoction of Angelica sinensis concentration conversion dose of making a living is 60mg/mL.
The NGM of configuration containing decocting liquid is dull and stereotyped:
Get rose wate decocting liquid, add in NGM culture medium, making the final concentration of rose wate decocting liquid in pastille NGM culture dish be scaled crude drug amount is 0.4mg/mL and 0.8mg/mL; Making the final concentration of water decoction of Angelica sinensis in pastille NGM culture dish be scaled crude drug amount is 1.2mg/mL and 2.4mg/mL; Making in pastille NGM culture dish when the final concentration of Flos Rosae Rugosae Radix Angelicae Sinensis compositions decocting liquid is scaled crude drug amount is 2.8mg/mL and 3.2mg/mL.Leave standstill and wait for culture medium solidifying.In culture medium, even spread escherichia coli OP50 is as the food of nematicide.
4. implementation step
(1) cultivation of nematicide:
Be connected on by nematicide and scribble on the solid NGM plate of escherichia coli OP50, the incubator being then placed in 16 DEG C is cultivated, and carries out synchronization process when nematicide grows to adult.
(2) nematicide synchronization:
Select containing a large amount of adult and the NGM culture medium having partial line worm's ovum to hatch, with M9 liquid, nematicide is swept away from culture medium, transfer in centrifuge tube, leave standstill and make, at the bottom of nematicide free settling to pipe, to abandon supernatant.How many sight line worm amounts adds lysate in centrifuge tube, whirlpool misfortune agitator vibrates 5-7 minute until nematicide complete rupture time stop vortex, and be sub-packed in 1.5mL centrifuge tube, wash line eggs three times with M9 solution.
(3) experimental group is arranged
Blank group (Control): sterilized water.
Rose wate decocting liquid low concentration group (R50): in the NGM plate of pastille, the final concentration of rose wate decocting liquid is 0.4mg/mL;
Rose wate decocting liquid high concentration group (R25): in the NGM plate of pastille, the final concentration of rose wate decocting liquid is 0.8mg/mL;
Water decoction of Angelica sinensis low concentration group (D50): in the NGM plate of pastille, the final concentration of water decoction of Angelica sinensis is 1.2mg/mL;
Water decoction of Angelica sinensis high concentration group (D25): in the NGM plate of pastille, the final concentration of water decoction of Angelica sinensis is 2.4mg/mL;
Flos Rosae Rugosae Radix Angelicae Sinensis compositions low concentration group (D25+R50): in the NGM plate of pastille, the final concentration of Flos Rosae Rugosae Radix Angelicae Sinensis compositions is 2.8mg/mL;
Concentration group (D25+R25) in Flos Rosae Rugosae Radix Angelicae Sinensis compositions: in the NGM plate of pastille, the final concentration of Flos Rosae Rugosae Radix Angelicae Sinensis compositions is 3.2mg/mL;
(4) experimental procedure
The line eggs be sub-packed in after synchronization in centrifuge tube is transferred to and is coated with OP50 and mixes in the NGM culture dish of the rose wate decocting liquid of variable concentrations, blank group is be coated with OP50 and be added with the NGM culture dish with the isopyknic sterilized water of rose wate decocting liquid, each culture dish 60 nematicides, each drug level three culture dishs, as parallel, cultivate 3 days to the L3 phase for 16 DEG C.Wherein, in pastille NGM culture dish, final concentration such as the experimental group of each group is arranged.
In order to make nematicide express A β, L3 phase nematicide being turned and induces at 25 DEG C, start after 34h to count nematicide paralysis number.Every two hours count once, until all nematicides are all benumbed (when paralysis refers to mechanical stimulus nematode body, nematicide can not move or only have head movement).The results are shown in Figure 1.
(5) experimental result
The vertical coordinate of Fig. 1 represents the percentage ratio that accounts for of Caenorhabditis elegans not having to benumb, and at point at the same time, this value is larger, shows not have the Caenorhabditis elegans ratio of paralysis in this processed group larger, and namely to delay the effect of paralysis stronger for medicine.
Experimental result shows, in the present embodiment alone Flos Rosae Rugosae or Radix Angelicae Sinensis, does not show the retarding action to AD nematicide muscular paralysis.After by the two Combination application, show, to AD nematicide muscular paralysis, there is significant retarding action.This shows that Flos Rosae Rugosae and Radix Angelicae Sinensis can play the anti-AD of synergism.
Embodiment 3 Flos Rosae Rugosae Radix Angelicae Sinensis composition dosage relies on the muscular paralysis that ground delays AD Caenorhabditis elegans
(1) experimental group is arranged
Blank group (Control): sterilized water.
Concentration group (D25+R25) in Flos Rosae Rugosae Radix Angelicae Sinensis compositions: in the NGM plate of pastille, the final concentration of Flos Rosae Rugosae Radix Angelicae Sinensis compositions is scaled crude drug amount is 3.2mg/mL;
Flos Rosae Rugosae Radix Angelicae Sinensis compositions high concentration group (D12.5+R12.5): in the NGM plate of pastille, the final concentration of Flos Rosae Rugosae Radix Angelicae Sinensis compositions is scaled crude drug amount is 6.4mg/mL;
(2) other laboratory operating procedures is with embodiment 2.
(3) experimental result
The vertical coordinate of Fig. 2 represents the percentage ratio that accounts for of Caenorhabditis elegans not having to benumb, and at point at the same time, this value is larger, shows not have the Caenorhabditis elegans ratio of paralysis in this processed group larger, and namely to delay the effect of paralysis stronger for medicine.
Experimental result shows, Flos Rosae Rugosae Radix Angelicae Sinensis composition dosage relies on the muscular paralysis that ground delays AD Caenorhabditis elegans.
Proved by above embodiment, Flos Rosae Rugosae Radix Angelicae Sinensis compositions provided by the invention plays significant synergistic therapeutic action to Caenorhabditis elegans AD pathological model, Flos Rosae Rugosae Radix Angelicae Sinensis compositions provided by the invention is pointed out to have treatment Alzheimer's disease potentiality, can apply in the medicine of preparation treatment Alzheimer's disease, also can apply in the health product of preparation prevention Alzheimer's disease.
Claims (6)
1. treat a Flos Rosae Rugosae Radix Angelicae Sinensis compositions for Alzheimer's disease, it is characterized in that, described compositions contains Flos Rosae Rugosae, Radix Angelicae Sinensis.
2. a kind of Flos Rosae Rugosae Radix Angelicae Sinensis compositions for the treatment of Alzheimer's disease as claimed in claim 1, it is characterized in that, described compositions contains the crude drug of following weight ratio: Flos Rosae Rugosae 2-4 part, Radix Angelicae Sinensis 12 parts.
3. the application of the Flos Rosae Rugosae Radix Angelicae Sinensis compositions as described in any one of claim 1-2 in the medicine of preparation treatment Alzheimer's disease.
4. apply as claimed in claim 3, it is characterized in that, described Flos Rosae Rugosae Radix Angelicae Sinensis compositions is capsule, tablet, granule, powder, oral liquid, pill as the pharmaceutical preparation of active ingredient.
5. the application of the Flos Rosae Rugosae Radix Angelicae Sinensis compositions as described in any one of claim 1-2 in the health product preparing prevention and auxiliary treatment Alzheimer's disease.
6. apply as claimed in claim 5, it is characterized in that, described Flos Rosae Rugosae Radix Angelicae Sinensis compositions is capsule, tablet, granule, powder, oral liquid, pill as the health product dosage form of effective ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937743.6A CN105395643B (en) | 2015-12-16 | 2015-12-16 | A kind of rose Radix Angelicae Sinensis composition for treating Alzheimer's disease and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510937743.6A CN105395643B (en) | 2015-12-16 | 2015-12-16 | A kind of rose Radix Angelicae Sinensis composition for treating Alzheimer's disease and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105395643A true CN105395643A (en) | 2016-03-16 |
| CN105395643B CN105395643B (en) | 2018-01-05 |
Family
ID=55461639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510937743.6A Active CN105395643B (en) | 2015-12-16 | 2015-12-16 | A kind of rose Radix Angelicae Sinensis composition for treating Alzheimer's disease and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105395643B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912597A (en) * | 2010-08-27 | 2010-12-15 | 葛德钜 | Medicament for treating senile dementia and preparation method thereof |
| CN103446317A (en) * | 2012-05-30 | 2013-12-18 | 王雪丽 | Traditional Chinese medicine for curing senile dementia |
| CN104474429A (en) * | 2014-12-30 | 2015-04-01 | 兰州古驰生物科技有限公司 | Traditional Chinese medicine preparation with function of reducing hypomnesis |
-
2015
- 2015-12-16 CN CN201510937743.6A patent/CN105395643B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101912597A (en) * | 2010-08-27 | 2010-12-15 | 葛德钜 | Medicament for treating senile dementia and preparation method thereof |
| CN103446317A (en) * | 2012-05-30 | 2013-12-18 | 王雪丽 | Traditional Chinese medicine for curing senile dementia |
| CN104474429A (en) * | 2014-12-30 | 2015-04-01 | 兰州古驰生物科技有限公司 | Traditional Chinese medicine preparation with function of reducing hypomnesis |
Non-Patent Citations (1)
| Title |
|---|
| 侯三喜: "《生活方式与老年痴呆防治》", 31 March 2015, 第四军医大学出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105395643B (en) | 2018-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103584106A (en) | Composition capable of improving bone mineral density | |
| CN109549961A (en) | A kind of application of Chinese medical extract in the drug of preparation treatment Alzheimer's disease | |
| JP2013032308A (en) | Pharmaceutical composition for treating/preventing depression | |
| CN107233382B (en) | Application of traditional Chinese medicine composition in preparation of drugs or health-care products for preventing or treating AD | |
| CN111437323A (en) | Application of vine tea extract in medicine for preventing and treating Alzheimer disease | |
| CN103156876A (en) | Medicine composition for treating central nervous system diseases and preparation method and application thereof | |
| CN105521076A (en) | Traditional Chinese medicine composition containing flos rosae rugosae and used for treating Alzheimer disease and application of composition | |
| CN103040905B (en) | Herba arenariae kansuensis or the purposes of its extract in the antidotal medicine of preparation or health food | |
| CN103768171B (en) | Chinese medicine composition of antidepressant, bactericidal antiphlogistic and preparation method thereof | |
| CN105395643A (en) | Rose-angelica sinensis composition for treating Alzheimer's disease and application thereof | |
| CN109498703B (en) | Application of radix codonopsis and fructus lycii composition in preparation of medicine for treating Alzheimer's disease | |
| CN109453159B (en) | Application of valeriana jatamansi jones extract monomer compound in preparation of anti-AD drugs | |
| CN105521269A (en) | Rose composition for treating Alzheimer disease and application of rose composition | |
| CN106563061B (en) | Yuye decoction composition for treating Alzheimer disease | |
| KR101470241B1 (en) | Pharmaceutical composition for the prevention or treatment of depression | |
| CN105147964A (en) | Rose-containing traditional Chinese medicine composition for treating Alzheimer's disease and application of traditional Chinese medicine composition | |
| CN107260780B (en) | Traditional Chinese medicine composition for treating rheumatic arthritis | |
| CN105521075A (en) | Rose essential oil for treating Alzheimer disease and application of rose essential oil | |
| CN114306543B (en) | Traditional Chinese medicine composition for treating Alzheimer disease and preparation method and application thereof | |
| CN109549972B (en) | Application of traditional Chinese medicine composition in preparation of anti-Parkinson's disease medicine | |
| CN105477008B (en) | Application of the rose polysaccharide in the medicine for preparing treatment Alzheimer's disease | |
| CN111920823B (en) | Application of danshenlactone in preparing medicine for treating Parkinson's disease | |
| CN113842406A (en) | Application of mulberry aqueous extract in preparation of medicine for treating Alzheimer's disease | |
| CN109847044B (en) | Application of Sishen water extract in preparation of drug for resisting Parkinson's disease | |
| CN113018287A (en) | Application of compound in preparation of medicine for eliminating abnormal protein aggregation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |